Inactive Total Small Business Set-Aside (FAR 19.5)

Amendment Two The following combined synopsis solicitation is amended to correct the following: “GSA E-buy” was removed, and then corrected language was added to state: QUOTES DUE: All quotes are due ... Amendment Two The following combined synopsis solicitation is amended to correct the following: “GSA E-buy” was removed, and then corrected language was added to state: QUOTES DUE: All quotes are due electronically by to Patricia Natividad, email Patricia.Natividad@fda.hhs.gov, no later than May 2, 2024, 10:00 a.m. Eastern Standard Time. Quotes shall be valid for 120 days. All other terms and conditions remain the same **************************************************************************************** Amendment One 75F40124Q00146_A00001: The Combined Synopsis/Solicitation is extended till May 2, 2024 at 10 am EST. All other terms and conditions remain the same. This is a combined synopsis/solicitation for commercial services prepared in accordance with the format in FAR 12.6 as supplemented with FAR 13 and additional information included in this notice. The incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2024-03, effective 02/23/2024. THIS ANNOUNCEMENT CONSTITUTES THE ONLY SOLICITATION AND A SEPARATE SOLICITATION WILL NOT BE ISSUED. The solicitation number for this acquisition is 75F40124Q00146 and is being issued as a Request for Quote (RFQ). The NAICS Code for this solicitation is 334516 and the Small Business Size Standard is 1,000 employees. This will be awarded as Firm-Fixed Price and competed as Small Business set-aside. Prospective Offerors are responsible for downloading the solicitation and any amendments from SAM.gov. The Government reserves the right to award an order without discussions if the Contracting Officer determines that the initial offer is providing the Best Value and discussions are not necessary. The Government intends to issue a Purchase Order. The U.S. Food and Drug Administration (FDA) has a need to procure liquid chromatograph (LC) coupled to a gas chromatograph (GC) for the analysis of mineral oil hydrocarbons (MOH) and sterols in fats and oils. Please see attached Combined Synopsis_Solicitation in full text.